I Kr Inhibitors
2 drugsAbout I Kr
I Kr, the rapidly activating delayed rectifier potassium current, is crucial for the repolarization phase of the cardiac action potential. Blocking IKr prolongs the action potential duration and the QT interval, which can be both therapeutically beneficial and potentially fatal.
IKr is a significant target in cardiovascular drug development, though there is currently no genetic evidence directly linking IKr to specific diseases. Excessive IKr blockade can lead to Torsades de Pointes, requiring careful drug consideration and monitoring.
Two FDA-approved small molecule drugs, DOFETILIDE (Aurobindo Pharma) and TIKOSYN (Pfizer), target IKr in the cardiovascular therapeutic area for managing heart rhythm disorders. These drugs were approved in 1999 and 2019, respectively.
Top I Kr Drugs
The competitive landscape includes Aurobindo Pharma and Pfizer, each with approved drugs.
Low market concentration suggests relatively low barriers to entry for new competitors.
I Kr Drug Modality Landscape
Modalities
Routes of Administration
I Kr is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or gene therapies represents a whitespace opportunity.
I Kr Clinical Trials 5 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on I Kr. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
I Kr Drug Approval Timeline (1999 - 2019)
The approval timeline spans 21 years, with the first drug approved in 1999 and the most recent in 2019.
The slow approval rate indicates potential challenges in developing IKr-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on I Kr. A trial counts if an approved drug acting on I Kr is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.